Drug intelligence / Profile preview

ANT-638

Development stage: Preclinical
Lead developer: Roche
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Ophthalmic, Intravitreal

Overview

ANT-638 is a bispecific antibody designed for ophthalmology that engages frizzled class receptor 4 (FZD4) as an agonist and inhibits low-density lipoprotein receptor-related protein 6 (LRP6), aiming to activate Wnt/β-catenin signaling in retinal vasculature for diseases such as retinal disorders and glaucoma. It is being developed by AntlerA Therapeutics, with current development in the preclinical stage in eye disease indications including retinal diseases and glaucoma.[5][1]

Targets

FZD4 (Frizzled class receptor 4)LRP6 (Low-density lipoprotein receptor-related protein 6)

Beyond the preview

Go deeper on ANT-638.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ANT-638.

Explore the full profile